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ABSTRACT
The Human Phenotype Ontology (HPO, https://hpo.
jax.org) was launched in 2008 to provide a com-
prehensive logical standard to describe and com-
putationally analyze phenotypic abnormalities found
in human disease. The HPO is now a worldwide
standard for phenotype exchange. The HPO has
grown steadily since its inception due to consid-
erable contributions from clinical experts and re-
searchers from a diverse range of disciplines. Here,
we present recent major extensions of the HPO for
neurology, nephrology, immunology, pulmonology,
newborn screening, and other areas. For example,
the seizure subontology now reflects the Interna-
tional League Against Epilepsy (ILAE) guidelines and
these enhancements have already shown clinical va-
lidity. We present new efforts to harmonize computa-
tional definitions of phenotypic abnormalities across
the HPO and multiple phenotype ontologies used for
animal models of disease. These efforts will benefit
software such as Exomiser by improving the accu-
racy and scope of cross-species phenotype match-
ing. The computational modeling strategy used by
the HPO to define disease entities and phenotypic
features and distinguish between them is explained
in detail.We also report on recent efforts to translate
the HPO into indigenous languages. Finally, we sum-
marize recent advances in the use of HPO in elec-
tronic health record systems.
INTRODUCTION
The Human Phenotype Ontology (HPO) is a comprehen-
sive resource that systematically defines and logically or-
ganizes human phenotypes. As an ontology, HPO enables
computational inference and sophisticated algorithms that
support combined genomic and phenotypic analyses. Broad
clinical, translational and research applications using the
HPO include genomic interpretation for diagnostics, gene-
disease discovery, mechanism discovery and cohort ana-
lytics, all of which assist in realizing precision medicine.
We have developed open community resources consisting
of the HPO ontology and a comprehensive corpus of dis-
ease HPO phenotype annotations (HPOA) corresponding
to each of nearly eight thousand rare diseases. Together with
other terminologies and classifications, the HPO and its dis-
ease annotations enable semantic interoperability in digital
medicine. Community contributions have added depth, cov-
erage, and sophistication to the HPO since its founding in
2008 (1–4). The HPO team welcomes additional contribu-
tions from consortia or individuals; see https://hpo.jax.org/
app/help/collaboration.
The HPO differs from other available clinical terminolo-
gies in several crucial ways. First, the HPO has substantially
deeper and broader coverage of phenotypes than any other
clinical terminology. In 2014, Bodenreider and colleagues
compared the HPO’s coverage of phenotypes to the com-
bined coverage of all other relevant terminologies in the
United Medical Language System (UMLS) and found that
the UMLS resources covered only about 35% of the con-
cepts in the HPO (5). This led to the HPO being incorpo-
rated into the UMLS (in collaboration with the HPO team).
Second, the HPO is not a simple terminology, but rather a
full Web Ontology Language (OWL) ontology and thus a
computational resource that allows sophisticated analyses,
including logical inference (6). Finally, the HPO-based com-
putational disease models are utilized within most, if not all,
current phenotype-driven genomic diagnostics software (7–
15).
As of 15 September 2020, the HPO contained 15 247
terms, representing a 9.3% increase since the last Nu-
cleic Acids Research (NAR) manuscript (Figure 1). The
HPOAs are computational disease models with associated
HPO terms. For instance, the disease Marfan syndrome
is characterized by––and therefore annotated to––over
50 phenotypic abnormalities including Aortic aneurysm
(HP:0004942) (each abnormality is represented by an HPO
term). The annotations can have modifiers that describe the
age of onset and the frequencies of features. For instance,
the phenotypic abnormality Brachydactyly (HP:0001156) is
rare in Hydrolethalus syndrome (3/56 according to a pub-
lished study referenced in our data) but affects nearly 100%
of patients diagnosed with most of the 484 other diseases
annotated to this term. This type of information can be used
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Figure 1. HPO terms organized by organ system. (A) Counts for top-level phenotype terms (direct descendants of Phenotypic abnormality (HP:0000118)
are shown. Counts of terms added to the ontology after the previous article in this series (19) are shown in dark blue (added between 25 July 2018 and
18 August 2020). (B) Examples of new terms added 2018–2020 and their parent terms, for selected organ systems. (C) An example text definition and
synonyms for a new term.
The HPO provides annotations to diseases defined by
Online Mendelian Inheritance in Man (OMIM) (17), nearly
all of which are monogenic (Mendelian) diseases. Currently,
93 885 of a total of 108 580 such annotations were de-
rived from mining the Clinical Synopsis section of the corre-
sponding entry. 14 695 (13.5%) annotations were produced
by curation by the HPO team and often contain additional
information such as age of onset, affected sex, clinical modi-
fiers, or overall frequency of the feature. A total of 7801 dis-
eases are annotated in this way, corresponding to 108 580
annotations in all (with a mean of 13.9 annotations per dis-
ease). 296 curated annotations to 47 chromosomal diseases
identified by DECIPHER (18) accessions were also gener-
ated by the HPO team (mean 6.2 annotations per disease).
In parallel, Orphanet uses the HPO to annotate rare dis-
eases and has continued to develop annotations to a broad
range of diseases (currently 96 612 annotations utilizing
7495 distinct HPO terms for 3956 diseases, with an aver-
age of 24.4 terms per disease). These annotations include
information about the frequency (obligatory, very frequent,
frequent, occasional, very rare or excluded) and whether
the annotated HPO term is a major diagnostic criterion
or a pathognomonic sign of the rare disease. These data
are available at Orphadata.org and in the HPO-Orphanet
Rare Disease Ontology (ORDO) ontological module called
HOOM (See Data Availability section, below). While some
of the annotated diseases overlap, Orphanet contains in-
formation about non-Mendelian rare diseases and defines
diseases primarily based on clinical criteria, thereby pro-
viding a complementary resource. Both sets of annotations
are available in a combined annotation file available on the
HPO website. Figure 2 displays the growth in annotations
to the OMIM entries.
Abnormal phenotypic features or manifestations of hu-
man disease stored in HPO are also employed for medical
research projects such as SOLVE-RD. Funded by the Euro-
pean Commission, SOLVE-RD aims to solve large numbers
of rare diseases for which a molecular cause is not known.
The HPO has a sophisticated quality control pipeline. In
addition to custom software, we make extensive use of the
quality control checks implemented in ROBOT (‘ROBOT
is an OBO Tool’) (47). We have added descriptions of our
quality control processes to the HPO website under the
Help menu.
COMMUNITY COLLABORATIONS TO EXTEND THE
COVERAGE OF HPO
The UK’s National Institute for Health Research (NIHR)
Rare Disease initiatives extensively use the HPO in their
RD-TRC (Rare Disease|-Translational Research Collabo-
ration) and NIHR BioResource, in wide-ranging studies.
Following an HPO workshop with members of the NIHR-
RD-TRC in 2017, the NIHR-RD-TRC assessed the matu-
rity of the HPO across different disease areas and organ
systems. Disorders of the immune system, central nervous
system, the respiratory system, and the kidney were among
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Figure 2. Annotations. Disease annotations using HPO terms organized by organ system. (A) Annotation counts for top-level phenotype terms (direct
descendants of Phenotypic abnormality HP:0000118) are shown. Counts of annotations added to the ontology after the previous article in this series (19)
are shown in dark blue (added between 25 July 2018 and 18 August 2020). Short forms are used to indicate the top level terms; for instance, ‘Ear’ indicates
Abnormality of the ear (HP:0000598). (B) Example new annotation.
In this article, we report on our work in these areas with
clinical experts.
Epilepsy
The epilepsies are a group of diverse disorders that share
a predisposition to seizures (20). They are phenotypically
complex with constellations of clinical features indicat-
ing different age-specific syndromes, broad epilepsy types,
and etiologies that guide clinical management (21). We
have recently demonstrated that phenotypic similarity ap-
proaches based on HPO-related phenotypes in the epilep-
sies can be used to identify novel genetic etiologies such
as AP2M1 (22), to map the natural history of genetic
epilepsies over time from electronic medical records (23),
and to identify patterns of gene-phenotype associations
(Figure 3) (24).
Given the release of a new International League Against
Epilepsy (ILAE) seizure classification (25), a revision of the
seizure subontology of the HPO was performed, supported
by the ILAE Epilepsiome Task Force. This project com-
menced with a week-long workshop in 2018 followed by
fortnightly teleconferences held over the following year to
coordinate a draft ontology created on WebProtégé (26). In
addition to the new classification of seizure types (25), the
new subontology integrates concepts from other proposed
classifications of status epilepticus (27), reflex seizures (28),
neonatal seizures (29), seizure semiology (30) and the liter-
ature of febrile seizures (31–34).
An important challenge in seizure classification is that
seizures are paroxysmal, and often incompletely character-
ized or observed. In order to maximize the available infor-
mation, the revised subontology includes terms indepen-
dent of some of the dimensions of seizure description. For
example, the terms Focal aware seizure (HP:0002349) and
Focal motor seizure (HP:0011153) allow a true instance of
Focal aware motor seizure (HP:0020217) to be coded as
precisely as possible when knowledge of either the initial
manifestation or the preservation of awareness is unknown.
These concepts provide a way to categorize high-level, in-
complete information that often makes disease classifica-
tion difficult. Where possible, pre-existing terms were re-
tained for the benefit of legacy HPO data. A few inconsis-
tencies with contemporary seizure concepts were identified
and corrected, such as the previous relationship of Bilat-
eral tonic-clonic seizure with focal onset (HP:0007334) as a
type of Generalized-onset seizure (HP:0002197) rather than
Focal-onset seizure (HP:0007359). The new seizure subon-
tology currently contains 347 terms, which significantly in-
creases the detail with which seizures can be described (Fig-
ure 4).
Inborn errors of immunity (IEI)
Inborn errors of immunity (IEI), previously referred to
as primary immunodeficiencies (PID), involve a variable,
disorder-specific predisposition towards infections, immune
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Figure 3. HPO-based analyses demonstrate the clinical features associated with diagnostic variants in SCN1A in published cohorts with developmental
and epileptic encephalopathies of various known, or unknown but presumed genetic, etiologies. Fisher’s exact test p-value for each term indicates the
significance of the association between the HPO term and the presence of a diagnostic SCN1A variant in the cohort. (A) The frequency of HPO terms in
SCN1A variant carriers versus non-carriers regardless of age. (B) The same data presented to demonstrate the conceptual relationships between associated
features within the structure of the HPO. (A) and (B) modified from (24) with only a selection of terms labeled for legibility.
A B
Figure 4. (A) The number of seizure terms applicable to the same clinical data from 82 individuals, and (B) the total information content of seizure terms
of the same individuals according to the new and previous HPO seizure subontologies, where the information content of each term is equal to the negative
logarithm of the proportion of individuals annotated with the term (Lewis-Smith et al., manuscript in preparation).
granuloma formation, lymphoproliferation, etc.), and ma-
lignancies. Phenotypes of IEI are often complex, making
it difficult to distinguish primary disease-specific features
from secondary unspecific, infection- or inflammation-
related, or merely randomly occurring clinical manifesta-
tions. However, unequivocal phenotypic descriptions are
needed for semantic interoperability to enable the use of
defining, cross-referencing, and/or filtering algorithms dur-
ing the process of diagnosing these rare diseases. For the
purpose of data verification of entries into the large interna-
tional registry of the European Society for Immunodeficien-
cies (ESID) that includes data from >30 000 patients, either
a known genetic diagnosis or the fulfillment of working defi-
nitions for the clinical diagnosis of IEI is required. Together
with a group of international collaborators, the ESID reg-
istry working group designed a comprehensive list of oblig-
atory and optional criteria for 92 entities that lack a genetic
diagnosis (e.g. common variable immunodeficiency) that
were cross-validated by other experts in a two-phase process
(35). To enhance this catalog of clinical working definitions
of IEI, we recently added HPO terms and the frequencies of
phenotypes observed, derived from HOOM. For most other
IEIs that are included in the genotypic classification of the
International Union of Immunological Societies (36), com-
plete HPO term annotations are still lacking. To improve
the available vocabulary and annotated diseases, a targeted
expansion of IEI relevant HPO terms and re-annotation of
currently known IEIs was launched by representatives of
the ESID genetics working party and of ERN-RITA (Euro-
pean Network on Rare Primary Immunodeficiency, Autoin-
flammatory and Autoimmune diseases) with input from the
International Society of Systemic Autoinflammatory Dis-
eases (ISSAID) in 2018. The systematic review involved ex-
pert clinicians, geneticists, researchers (working on IEI) and
bioinformaticians combining an ontology-guided machine-
learning approach (37) with expert clinical immunologists’
reviews (M. Haimel, et al., manuscript in preparation). The
HPO-classification of IEI is part of The Medical Informat-
ics Initiative Germany (MII) founded by the Federal Min-
istry of Education and Research, which has launched the
Collaboration on Rare Diseases (CORD) project. Aided by
the national TRANSLATE-NAMSE project, this initiative
plays a key role in the development of digitalized patient
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dardized phenotypic patient information. Digital record-
ing of HPO terms will facilitate genetic research to iden-
tify disease-causing variants; it will also support large-scale
studies aiming to associate genetic variance with a plethora
of risks that can disrupt immune homeostasis.
Kidney Precision Medicine Project (KPMP)
The Kidney Precision Medicine Project (KPMP) aims to
understand and find ways to treat chronic kidney disease
(CKD) and acute kidney injury (AKI). KPMP has con-
tributed over 100 kidney-related phenotype terms; clinical
nephrologists, pathologists and ontologists worked together
over multiple workshops to propose new terms and modifi-
cations to HPO and underlying ontologies such as Uberon
(38). Two new major HPO branches were generated, one fo-
cusing on pathology-related terms, and the other on clinical
phenotype terms (Figure 5).
Pulmonology
The category of respiratory disorders is not only underrep-
resented in the HPO; it is rapidly expanding with the on-
going molecular definition of rare to ultra-rare novel dis-
eases. Therefore, substantial effort was undertaken to im-
prove the foundation and formulation of terms and dis-
ease associations. However, gaps remain–for example, for
most rare and common pulmonary disorders included in
the current classification of children’s interstitial lung dis-
eases (40), comprehensive HPO term annotations still need
to be completed. To this end, representatives of the Euro-
pean research collaboration for Children’s Interstitial Lung
Disease (chILD-EU) consortium have called for commu-
nity participation and initiated a low barrier approach to fa-
cilitate contribution to the HPO for newcomers (see section
on contributing to the HPO in the Data Availability sec-
tion, below). To facilitate sharing knowledge about rare res-
piratory disorders, information is collected in international
registers like the Kids Lung Register, operating through the
chILD-EU management platform. The chILD-EU network
utilizes the HPO, which significantly improved the catego-
rization of novel diseases and the annotation of cases in-
cluded for long term investigation (41).
Pharmacogenomics
HPO has introduced several terms to describe drug
response phenotypes. The new terms added to HPO
are branched under the term Abnormal drug response
(HP:0020169) and aim to encompass a spectrum of clinical
phenotypes with regards to drug metabolism. The underly-
ing HPO terms refer to abnormal blood concentration of
drugs, altered efficacy and adverse drug response. As phar-
macogenomic research makes its way into routine clinical
applications, such terms may be valuable in describing vari-
ance in drug metabolism as ascertained by laboratory inves-
tigation or genetic sequencing (42).
Newborn screening
Screening of newborns to facilitate the early identification,
diagnosis and treatment of rare diseases occurs through-
out the world. In the United States, the Newborn Screen-
ing Translational Research Network (NBSTRN) provides
tools and resources to researchers working to discover novel
screening technologies and interventions (43). An impor-
tant goal for the NBSTRN is to understand health out-
comes and the natural history of rare diseases by captur-
ing longitudinal genomic and phenotypic information on
the estimated 22 000 infants diagnosed through newborn
screening (NBS) each year. A US federal advisory commit-
tee recommends conditions for NBS resulting in the Rec-
ommended Uniform Screening Panel, and in 2018, screen-
ing for Spinal Muscular Atrophy was endorsed. As a case
study of HPO in NBS and rare disease, a REDCap™ data
dictionary of 4757 data elements in the SPOT SMA Lon-
gitudinal Pediatric Data Resource was reviewed to identify
existing terms and suggest new terms. The aim of this ef-
fort is to develop HPO as a resource for the longitudinal
followup of NBS identified individuals with the goal of ad-
vancing understanding of rare disease.
Interoperability with other phenotype ontologies
We have developed templated ontology design patterns to
structure OWL definitions, encoded as Dead Simple OWL
Design Patterns (DOSDPs) (44). DOSPDs provide a num-
ber of advantages, including standardized patterns for the
logical definitions and automatic classification. As coor-
dinators of the Phenotype Ontologies Reconciliation Ef-
fort (45, 46), HPO developers contributed to the definition
of 207 DOSDP templates for the consistent definition of
phenotypes across species and modalities (44). The Uni-
fied Phenotype Ontology (uPheno) integrates multiple phe-
notype ontologies into a harmonized cross-species pheno-
type ontology. uPheno enables the comparison and group-
ing of species-specific phenotypes under species-neutral cat-
egories, and links phenotypes from one species with com-
parable phenotypes from other species. Using templates
generates phenotype terms that are not only consistently
structured, but also enriched with associations to, for ex-
ample, biological processes (Gene Ontology), anatomical
entities, and molecular entities. For example, an abnormal
level of chemical entity with role in location provides a
template for terms such as Abnormal circulating hormone
level (HP:0003117). Reconciliation is ongoing and is im-
proving the alignment between phenotype ontologies for
a range of organisms including C. elegans, Dictyostelium
discoideum, Drosophila, fission yeast, planarian, Xenopus,
mammals (MP) and zebrafish (ZP), as well ontologies for
glycophenotypes (47) and pathogen–host interactions. The
goal is to enable meaningful and reliable mapping of phe-
notype data such as gene-to-phenotype associations across
databases that are specific to particular modalities or organ-
isms, and leverage this data for a variety of important appli-
cations including clinical diagnosis and variant prioritiza-
tion. For example, Exomiser (15) leverages the semantic as-
sociations between HPO, MP and ZP to prioritize variants
effectively by matching human phenotypic abnormalities
with phenotypes observed in animal models with knockouts
of genes orthologous to human disease-associated genes.
Figure 6 illustrates the extent to which phenotype on-
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Figure 5. One major goal of KPMP is to refine classification of kidney diseases in molecular, cellular, and phenotypic terms and thereby identify novel
targeted therapies. The kidney-related HPO terms are being used in multiple ways in KPMP. For example, KPMP has used the HPO terms for clinical
and pathological phenotype annotations, integrative Kidney Tissue Atlas Ontology (KTAO) (39) development, and systematic data integration software
development.
Figure 6. Proportions of terms defined in the HPO, the Mammalian Phe-
notype Ontology (MP) (48), the Drosophila Phenotype Ontology (DPO)
(49), the Worm Phenotype Ontology (WPO) (50), the Xenopus Phenotype
Ontology (XPO) (51) and the Zebrafish Phenotype Ontology (ZP) (52).
conformant’). Currently, the HPO has 6154 OWL-defined
terms (41% of the total number of 15 029 terms), out of
which 4139 (67%) adhere to an existing template. While
some phenotypes may be too complex to define using a gen-
eral template, we hope to increase our coverage to ∼50% of
the terms.
Indigenous languages
For equity and scale of precision medicine and precision
public health, it is critical to advance methods to improve
the diagnosis and treatment of rare diseases. Communica-
tion is critical to healthcare and methods to deliver and in-
corporate translations, community narratives and family-
based approaches are important to advancing culturally ap-
propriate care. Lyfe Languages (lyfelanguages.com) is im-
proving communication between indigenous patients, fam-
ilies, and medical professionals, in part by delivering in-
digenous language translations of the HPO. This started
with a focus on rare diseases, then expanded to also in-
clude COVID-19 and is being extended into mental health.
Currently, HPO terms are being translated to 11 Australian
Aboriginal and Torres Strait Islander Languages and 6
Ghanian indigenous languages. The latter project is being
performed together with the Rare Disease Ghana Initiative.
HPO for medical education & crowdsourcing
One of the advantages of the structured knowledge con-
tained in the HPO is that it can be utilized as a teaching
tool. One recent example of using HPO in this way is Phe-
notate, a portal that allows the annotation of OMIM and
Orphanet disorders with HPO terms to be formulated as as-
signments for students (53). Phenotate has been used in five
undergraduate courses, allowing for the collection of anno-
tations for 22 diseases, including six where previously struc-
tured annotations were not available. Interestingly, the an-
notations generated by Phenotate, while sourced from un-
trained undergraduate students, were equal to curated gold
standards in terms of allowing clinicians to identify rare dis-
orders.
EHR INTEGRATION
Electronic health records (EHRs) have been widely adopted
and offer an unprecedented opportunity to accelerate trans-
lational research because of advantages of scale and cost-
efficiency as compared to traditional cohort-based stud-
ies. Textual data within EHRs can describe phenotypic fea-
tures that are not encoded within the structured fields of the
EHR, but natural language processing (NLP) is required to
transform such data into terminological entities (ontology
terms) for downstream analysis. NLP of phenotypic data is
becoming a mature field that can be used to improve clinical
care, and HPO has been used by a number of groups as a
resource for EHR analysis (54). For example, EHRs span-
ning individuals’ entire childhoods can be mapped to the
HPO, yielding longitudinal patterns of phenotypic features
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Figure 7. Analysis of time-stamped EHRs of children with epilepsy demonstrates the association of HPO terms with diagnostic SCN1A variants at different
ages (modified from (23) with only a selection of terms labeled for legibility).
However, EHR data are often incomplete or incorrect, and
EHR systems are generally billing instruments rather than
tools to improve patient care, much less allow secondary re-
search.
LOINC (Logical Observations Identifiers, Names,
Codes) is a clinical terminology for laboratory test orders
and results that is widely used in EHRs (55). We developed
a mapping strategy (LOINC2HPO) to transform labora-
tory data in EHR records to HPO terms. For instance, if
the result of the test LOINC:6298-4 (potassium in blood)
is above normal limits, our library would call the HPO
term Hyperkalemia (HP:0002153). Many common tests in
medicine can be performed in multiple ways, so there can
be multiple LOINC codes for tests that measure the same
biological quantity. For instance, currently, there are four
different LOINC terms for different tests of urine nitrite.
Our library maps these terms to the same HPO term.
Additionally, the hierarchy of the HPO can be used to roll
up related results (e.g. reduced concentrations of different
B vitamins in the blood). In a pilot study, we investigated
EHR data from 15 681 patients with respiratory complaints
and identified known biomarkers for asthma (56). However,
the absence of an ontological structure in LOINC, a known
issue, impeded optimal information capture and coding.
Members contributing to last year’s paper have secured
funding to partner with the LOINC developer to address
this challenge, which will enhance the community’s ability
to categorize clinical laboratory findings into HPO terms.
The diagnostic decision support system SimulConsult
uses a controlled list of 9871 findings chosen for their impor-
tance in diagnosis (12). As part of a project to use machine-
assisted chart review to flag which of those findings are dis-
cussed in the EHR, hundreds of new findings were added
to HPO in a collaboration between HPO and SimulCon-
sult. Since HPO is one of the key inputs to the UMLS con-
cept codes, adding terms to HPO is an efficient workflow
for adding terms to UMLS as well.
Enabling large scale integration of biomedical knowl-
edge with clinical patient data requires robust and ac-
curate mappings between standardized clinical terminol-
ogy concepts and ontologies, like the HPO. Existing work
has demonstrated the power of the HPO to enrich clini-
cal data including craniofacial and oral phenotypes (57),
rare and Mendelian disease (58, 59), and infectious disease
(60). There have also been more generalized mapping ef-
forts aimed at aligning different clinical terminologies to
the HPO including free-text narratives (61) and structured
data like diagnosis codes (62, 63). While this work is very
promising, it has largely been limited to specific clinical do-
mains (i.e. only diagnosis codes from structured data or only
phenotype mentions in free-text). Additionally, the vast ma-
jority of prior work focused on mapping clinical codes
from standardized terminologies has exclusively focused on
mapping only specific terminologies (e.g. SNOMED-CT or
ICD-9). Mapping to a single terminology limits the general-
izability of the mappings. One solution is to generate map-
pings to common data models (CDM) as well as tools that
integrate different EHR data, such as Informatics for In-
tegrating Biology and the Bedside (i2b2) (64) and Obser-
vational Health Data Sciences and Informatics’s Observa-
tional Medical Outcomes Partnership (OMOP) (65).
Currently, there exist no large-scale mappings spanning
multiple clinical domains (e.g. diagnosis, medications, labo-
ratory measurements) to the HPO and other biomedical on-
tologies. In collaboration with researchers from the Univer-
sity of Colorado Anschutz Medical Campus, a new frame-
work, OMOP2OBO (66), is being developed to map sev-
eral ontologies, including the HPO, to standardized clinical
terminologies in the OMOP CDM. The mappings are gen-
erated using a combination of manual and automatic ap-
proaches and validated by a panel of clinical and biological
domain experts. To date, the mappings cover over 29 000 di-
agnosis codes (over 20 000 diagnosis codes map to a total
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over 11 000 laboratory test results including and extending
current LOINC2HPO annotations.
The distinction between diseases and phenotypes
The community uses the word phenotype with multiple
meanings. The HPO defines a disease as an entity that has
all four of the following attributes:
• an etiology (whether identified or as yet unknown)
• a time course
• a set of phenotypic features
• if treatments exist, there is a characteristic response to
them
A phenotype phenotypic feature is a part of a disease. The
phenotype of an individual with a disease can be said to
be the sum of all of the phenotypic features manifestated
by that individual. HPO terms can be used to describe the
phenotypic features that occur in individuals with a disease.
For instance, if the disease entity is the common cold, then
the cause is a virus; the phenotypic features include fever,
cough, runny nose, and fatigue; the time course usually is
a relatively acute onset with manifestations dragging on for
days to about a week; and the treatment may include bed
rest, aspirin, or nasal sprays. In contrast, a phenotypic fea-
ture such as fever is a manifestation of many diseases. There
is a grey zone between diseases and phenotypic features. For
instance, diabetes mellitus can be conceptualized as a dis-
ease, but it is also a feature of other diseases such as Bardet
Biedl syndrome. The HPO takes a practical stance and pro-
vides terms for such entities. In the future, the HPO will de-
velop tighter integration with the Mondo Disease Ontology
(67) in order to define this category of HPO terms based on
the corresponding diseases. A related issue is the fact that
phenotypic features are analyzed and reported at different
levels of granularity. For instance, the evaluation of a liver
biopsy in an individual with hepatitis C would usually in-
volve an assessment of focal lobular necrosis, portal inflam-
mation, piecemeal necrosis, and bridging necrosis, each of
which could be classified into one of several levels, each of
which would be specified in the pathology report. If the find-
ings are sufficiently abnormal, the pathologist may make a
diagnosis such as chronic hepatitis. For the purposes of pre-
cision medicine, it would be preferable to have all the infor-
mation available in electronic form, but in many settings,
not all of this information is available. The HPO takes a
practical stance, providing terms at different levels of granu-
larity; for example, Hepatic bridging fibrosis (HP:0012852)
and Chronic hepatitis (HP:0200123).
CONCLUSION
The HPO has continued to benefit from the support of do-
main experts from multiple areas of clinical medicine. We
will expand our work on extending the HPO terminology to
several additional subontologies including those for behav-
ioral abnormalities, various areas related to prenatal and
perinatal medicine, as well as to common diseases. We are
designing an online collaboration portal for domain experts
to submit new disease annotations.
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Kiper,N., Emiralioğlu,N., Snijders,D., Goldbeck,L. et al. (2018)
International management platform for children’s interstitial lung
disease (chILD-EU). Thorax, 73, 231–239.
42. Giannopoulou,E., Katsila,T., Mitropoulou,C., Tsermpini,E.-E. and
Patrinos,G.P. (2019) Integrating next-generation sequencing in the
clinical pharmacogenomics workflow. Front. Pharmacol., 10, 384.
43. Lloyd-Puryear,M., Brower,A., Berry,S.A., Brosco,J.P., Bowdish,B.
and Watson,M.S. (2019) Foundation of the newborn screening
translational research network and its tools for research. Genet. Med.,
21, 1271–1279.
44. Osumi-Sutherland,D., Courtot,M., Balhoff,J.P. and Mungall,C.
(2017) Dead simple OWL design patterns. J. Biomed. Semantics, 8, 18.
45. Matentzoglu,N., Balhoff,J.P., Bello,S.M., Boerkoel,C.F.,
Bradford,Y.M., Carmody,L.C., Cooper,L.D., Grove,C.A.,
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